Fine and Gray competing risk regression analysis for development of bleeding score
. | . | Univariate . | Multivariable . | ||||
---|---|---|---|---|---|---|---|
Risk factor . | . | SHR . | 95% CI . | P value . | SHR . | 95% CI . | P value . |
PT-INR | (>1.3-1.5 vs ≤1.3) | 8.49 | 2.80-25.79 | <.001 | 7.72 | 2.53-23.56 | <.001 |
(>1.5 vs ≤1.3) | 27.78 | 8.97-86.06 | <.001 | 22.46 | 6.92-72.91 | <.001 | |
LDH | (≥2 vs <2 × ULN) | 6.13 | 2.24-16.78 | <.001 | — | ||
Platelets | (≤40 vs > 40 × 109/L) | 4.78 | 1.75-13.08 | .002 | 3.63 | 1.31-10.05 | .010 |
Albumin | (<3 vs ≥3 g/dL) | 4.36 | 1.73-10.95 | .002 | — | ||
PTT | (≥35 vs <35S) | 4.58 | 1.64-12.80 | .004 | — | ||
Bilirubin | (>1.2 vs ≤1.2 mg/dL) | 1.97 | 1.07-3.64 | .030 | — | ||
NRAS | (yes vs no) | 2.59 | 1.04-6.47 | .042 | — | ||
WBC | (≥25 vs <25 × 109/L) | 2.49 | 1.02-6.09 | .045 | — | ||
Age | (≥60 vs <60 y) | 0.43 | 0.17-1.06 | .068 | — | ||
TET2 | (yes vs no) | 2.37 | 0.92-6.08 | .074 | — |
. | . | Univariate . | Multivariable . | ||||
---|---|---|---|---|---|---|---|
Risk factor . | . | SHR . | 95% CI . | P value . | SHR . | 95% CI . | P value . |
PT-INR | (>1.3-1.5 vs ≤1.3) | 8.49 | 2.80-25.79 | <.001 | 7.72 | 2.53-23.56 | <.001 |
(>1.5 vs ≤1.3) | 27.78 | 8.97-86.06 | <.001 | 22.46 | 6.92-72.91 | <.001 | |
LDH | (≥2 vs <2 × ULN) | 6.13 | 2.24-16.78 | <.001 | — | ||
Platelets | (≤40 vs > 40 × 109/L) | 4.78 | 1.75-13.08 | .002 | 3.63 | 1.31-10.05 | .010 |
Albumin | (<3 vs ≥3 g/dL) | 4.36 | 1.73-10.95 | .002 | — | ||
PTT | (≥35 vs <35S) | 4.58 | 1.64-12.80 | .004 | — | ||
Bilirubin | (>1.2 vs ≤1.2 mg/dL) | 1.97 | 1.07-3.64 | .030 | — | ||
NRAS | (yes vs no) | 2.59 | 1.04-6.47 | .042 | — | ||
WBC | (≥25 vs <25 × 109/L) | 2.49 | 1.02-6.09 | .045 | — | ||
Age | (≥60 vs <60 y) | 0.43 | 0.17-1.06 | .068 | — | ||
TET2 | (yes vs no) | 2.37 | 0.92-6.08 | .074 | — |
SHR, subdistribution hazard ratio; ULN, upper limit of normal.
Different cutoffs for fibrinogen (≥100 vs <100 and ≥150 vs <150 mg/dL) and PTT (≥40 vs <40S) yielded comparable results.